156 related articles for article (PubMed ID: 12482017)
1. Rebif offers another option for treating multiple sclerosis.
Ryan M
J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
[No Abstract] [Full Text] [Related]
2. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
3. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
4. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
[TBL] [Abstract][Full Text] [Related]
5. Shortcomings in pharmacy benefit forecasting--interferon beta products.
Rich SJ; Meyer C
J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
[No Abstract] [Full Text] [Related]
6. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
Hartung HP
Expert Opin Pharmacother; 2009 Feb; 10(2):291-309. PubMed ID: 19236200
[TBL] [Abstract][Full Text] [Related]
7. Funding of drug treatment of multiple sclerosis should not be delayed.
Paty DW
BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
[No Abstract] [Full Text] [Related]
8. Interferon beta in multiple sclerosis.
Richards RG
BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
[No Abstract] [Full Text] [Related]
9. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
10. Injecting rationale into interferon-beta therapy.
Reder AT; Antel JP
Neurology; 2000 Jun; 54(11):2034-5. PubMed ID: 10851357
[No Abstract] [Full Text] [Related]
11. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
Sumino R
Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
[No Abstract] [Full Text] [Related]
13. Beta interferon and multiple sclerosis: why the fuss?
Mumford CJ
QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
[No Abstract] [Full Text] [Related]
14. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
Bryant J; Clegg A; Milne R
BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
[No Abstract] [Full Text] [Related]
15. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta 1a.
Pozzilli C; Koudriavtseva T
Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple sclerosis with interferon beta 1b.
Dhib-Jalbut S; McFarland HF
Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
[TBL] [Abstract][Full Text] [Related]
19. Bad decision NICE.
Ellis SJ
Lancet; 2002 Feb; 359(9304):447. PubMed ID: 11844551
[No Abstract] [Full Text] [Related]
20. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Devonshire VA; Verdun di Cantogno E
Ther Deliv; 2011 Nov; 2(11):1455-65. PubMed ID: 22844681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]